gonorrhea resistance increasing??

A rather disturbing MMWR just came out finding that gonorrhea is becoming increasingly resistant to pretty much all of our current antibiotics (see  http://www.cdc.gov/mmwr/volumes/65/ss/pdfs/ss6507.pdf ). Details:

--the Gonococcal Isolate Surveillance Project (GISP) has been around since 1986 and does sentinel surveillance of antimicrobial sensitivity for N. gonorrhoeae (GC). They check GC cultures and antibiotic susceptibility from the first 25 men with gonococcal urethritis attending each of the participating STD clinics at 27 sites in the US.
--they are able to extract selected demographic and clinical data
--mean age 28, 58% Black/22% white/13%Hispanic-Latino; 37% MSM or MSMF (men who have sex with men, or both men and women)
--results:
                --5093 isolates were collected in 2014 (all of the resistance patterns were more common in MSM)
                                --25.3% resistant to tetracyclines
                                --19.2% resistant to ciprofloxacin (increasing, though there was an initial dip after the CDC stopped recommending its use to treat GC)
                                --16.2% resistant to penicillin (plasmid-based, chromosomal, or both) -- though CDC has not recommended using it for treatment of GC since 1989
                --but of major significance:
                                --2.5% had reduced susceptibility to azithromycin (0.6% in 2013):
                                                --in all geographic areas of the US, but most in the Midwest (Midwest about 4%, Northeast about 2.7%, rest about 2%)
                                                --in all groups of sex partners (MSM about 4.3%, MSMW about 3.2%, and MSW about 1.5%)
                                                --none of these azithro-resistant isolates had reduced ceftriaxone or cefixime susceptibility
                                --0.8% had reduced susceptibility to cefixime (0.4% in 2013)
                                --0.1% had reduced susceptibility to ceftriaxone (no change from 2013), though highest in Northeast (about 0.4%).
                                ​--38% of isolate exhibited resistance to some antibiotic;  and 10% to 2, 7% to 3 and 0.5% to 4 antibiotics

Commentary:
--gonorrhea is the 2nd most commonly reported notifiable disease in the US, with 350,062 cases reported in 2014
--the role of GISP is especially important, since we have mostly gone to NAAT testing (nucleic acid amplification tests) instead of GC culture, and one needs to grow the GC in culture to test susceptibility
--though the numbers of resistant isolates to the azithro and ceftriaxone are still pretty low, it is important to remember that there is a critical threshold (inflection, or tipping point), where the prevalence leads to a dramatic increases in their transmission (which, from my rather distant memory is on the order of 8%). So the 4-fold increase in azithro resistance to 2.5% may be really foreboding
--limitations of the study: a big one is that only men with urethritis were tested (and MSM,MSMW were disproportionately represented); another is that we do need to see infectious diseases more and more through a global perspective. What is happening in the US is not isolated from the rest of the world. And though the resistance level to ceftriaxone is still relatively low in the US, in other areas the levels are much higher (the WHO report in 2014 found >25% resistance to 3rd generation cephalosporins in 3 of the 6 regions of the world. See http://gmodestmedblogs.blogspot.com/2014/05/who-report-on-antimicrobial-resistance.html  for details.)  Also, with such low numbers of resistance reported by GISP (especially for ceftriaxone), sampling error could lead to rather large % changes in the numbers (only about 1% of the reported cases were actually sampled, and my guess is that there are many more cases of GC than those reported….)
--CDC recommendations remain the same: treat GC with ceftriaxone 250mg IM plus azithro 1gm orally (the combined meds are synergistic and cover for each other’s resistance for now, since there are no reported cases of resistance to both). Use azithro 2g plus gentamicin or gemifloxacin if intolerant of cephalosporins. Cefixime had been considered an acceptable cephalosporin to use until 2012, when recommendations changed because of increasing cefixime resistance. The decreasing cefixime resistance reported now may not be significant, since it is not simultaneously decreasing in other areas of the world. It is still not recommended by the CDC.
--and, the striking increase in azithromycin is very concerning because if it continues to increase, the mainstay of GC treatment will become increasingly ineffective, especially in the context of increasing cephalosporin resistance in much of the world. GC may become effectively resistant to all meds we currently have….

For a slew of blogs on antimicrobial resistance, see http://gmodestmedblogs.blogspot.com/search/label/antibiotic%20resistance

Comments

Post a Comment

if you would like to receive the near-daily emails regularly, please email me at gmodest@uphams.org

Popular posts from this blog

cystatin c: better predictor of bad outcomes than creatinine

  another article found significant discordance between creatinine and cystatin C in assessing renal function,  finding that the latter correlated most strongly with both renal and non-renal adverse clinical outcomes (see   ckd cystatin c better than creat AJKD2023  in  dropbox or doi: 10.1053/ j.ajkd.2023.04.002)   Details: -- 158,601 adults who were in the Stockholm Creatinine Measurements (SCREAM) project and had testing of creatinine and cystatin C on the same day during a healthcare encounter, from 2010-2018     -- >400,000 outpatient tests were done for both creatinine and cystatin C levels -- mean age 62, 48% female -- mean eGFR by creatinine (   eGFR cr ) 80; mean eGFR by cystatin C ( eGFR cys  ) 73 -- mean stage of renal insufficiency: 39%  eGFR cr   90+; 38%  eGFR cr  60-89; 12%  eGFR cr  45-59; 7.1%  eGFR cr  30-44; 3.2%  eGFR cr  15-29, 0.7%  eGFR cr ...
Read more

diabetes DPP-4 inhibitors and the risk of heart failure

the FDA just came out with a safety alert about 2 DPP-4 inhibitors and the increased risk of heart failure (released 04/05/2016)(see  http://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm494252.htm?source=govdelivery&utm_medium=email&utm_source=govdelivery ​ ). details: --saxagliptin and alogliptin were singled out because of 2 clinical trials in diabetic patients with heart disease. in each trial more patients taking these meds were hospitalized for heart failure vs those on placebo     --in the saxagliptin trial: 3.5% were hospitalized for heart failure (vs 2.8% on placebo). risk factors included prior heart failure or kidney disease     --in the alogliptin trial: 3.9% were hospitalized for heart failure (vs 3.3% on placebo) --recommendation by the FDA:     -- we should consider stopping these drugs if the patient develops heart failure ...
Read more

UPDATE: ASCVD risk factor critique

I decided to do an extensive update of my prior ASCVD (atherosclerotic cardiovascular disease) risk analysis and critique of risk calculators, with much more information about the “non-traditional” risk factors. I felt that there should be more data/clarification, since I think we are really undertreating/not preventing the most common cause of death by relying on the current ASCVD risk calculators   -- Cardiovascular risk models:      -- many of us rely on the various cardiovascular risk models to determine the appropriate approach to patients, and these are often integrated into the electronic medical records      -- these risk models have several very important limitations:          -- they are typically based on community data, eg from the Framingham study etc. But, in clinical practice, we are dealing with the individual and not the community:          ...
Read more